Abstract
Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Current Aging Science
Title: Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews
Volume: 3 Issue: 3
Author(s): Akiko Yamashita, Eberhard Fuchs, Masato Taira and Motoharu Hayashi
Affiliation:
Keywords: Normal aging, blood vessel, amyloid deposit, Congo red, Alzheimer’s disease, Tupai belangeri.
Abstract: Background: Amyloid beta (Aβ) accumulates in the human brain in an age-dependent manner during normal aging. However, Aβ accumulation has not been observed in rodents during normal aging. Tree shrews, the experimental animals studied here, are as small as rats but have a longer life span than rodents.
Methods: We investigated Aβ accumulations in the brains of young and aged tree shrews by amyloid histochemistry and immunohistochemistry using antibodies to Aβ-42, Aβ-40, Aβ-16 and amyloid precursor protein (APP).
Results: In the brain of young tree shrews, there were no Aβ- immunoreactive (-ir) and APP-ir profiles. In the brains of aged tree shrews, Aβ-42-ir neuronal profiles were observed in the cortex, subiculum, basal ganglia, mammillary body and hypothalamus, but there were only a few weak Congo red-positive amyloid deposits. Aβ-42-, Aβ-40-, Aβ-16- and APP-ir blood vessels were observed.
Conclusions: An early stage of amyloid accumulation occurs in the brains of aged tree shrews, indicating that this animal may be a good model for studying the start of Aβ accumulation.
Export Options
About this article
Cite this article as:
Yamashita Akiko, Fuchs Eberhard, Taira Masato and Hayashi Motoharu, Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews, Current Aging Science 2010; 3 (3) . https://dx.doi.org/10.2174/1874609811003030230
DOI https://dx.doi.org/10.2174/1874609811003030230 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Quercetin against Mycotoxin Induced Cytotoxicity: A Mini- Review
Current Nutrition & Food Science MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells
Recent Patents on Anti-Cancer Drug Discovery Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism HDL Therapy: Two Kinds of Right?
Current Pharmaceutical Design Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Current Medicinal Chemistry Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Current Gene Therapy Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry